{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:17:45Z","timestamp":1778923065240,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54NS115054"],"award-info":[{"award-number":["U54NS115054"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.medj.2026.101036","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:47:09Z","timestamp":1775836029000},"page":"101036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autologous CD19\/BCMA CAR-T cell therapy for myasthenia gravis: Advancing care for those with severe disease"],"prefix":"10.1016","volume":"7","author":[{"given":"Henry J.","family":"Kaminski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda L.","family":"Kusner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101036_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2026.101026","article-title":"Single-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19\/BCMA CAR-T cell therapy","volume":"7","author":"Ruan","year":"2026","journal-title":"Med"},{"key":"10.1016\/j.medj.2026.101036_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179742","article-title":"Myasthenia gravis: the future is here","volume":"134","author":"Kaminski","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.medj.2026.101036_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","article-title":"CAR-T cell therapy embarks on autoimmune disease","volume":"60","author":"Rampotas","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.medj.2026.101036_bib4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101036_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-04171-y","article-title":"BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial","author":"Vu","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101036_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aeb6424","article-title":"BCMA\/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares","volume":"12","author":"Huang","year":"2026","journal-title":"Sci. Adv."},{"key":"10.1016\/j.medj.2026.101036_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-04170-z","article-title":"BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial","author":"Fedak","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.medj.2026.101036_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1608160","article-title":"Subtype-specific atypical B cell profiles in myasthenia gravis reveal distinct immunopathological pathways","volume":"16","author":"Sikorski","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.medj.2026.101036_bib9","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3389\/fneur.2020.00660","article-title":"MuSK-Associated Myasthenia Gravis: Clinical Features and Management","volume":"11","author":"Rodolico","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.medj.2026.101036_bib10","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","article-title":"A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis","volume":"392","author":"Nowak","year":"2025","journal-title":"N. Engl. J. Med."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026000395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026000395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:00:47Z","timestamp":1778922047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026000395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666634026000395"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101036","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autologous CD19\/BCMA CAR-T cell therapy for myasthenia gravis: Advancing care for those with severe disease","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101026","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101036"}}